Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A
Condition: Charcot-Marie-Tooth Disease, Type IA Intervention: Drug: PXT3003 Sponsors: Pharnext SA; SynteractHCR; INC Research Not yet recruiting - verified January 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Charcot-Marie-Tooth Disease